First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Cited by (1,001)

Items 401–500 of 1,001

1. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
   Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, Elisabetta Zulato, Lorenzo Calvetti, Giulia Pasello, Valentina Guarneri, PierFranco Conte, Stefano Indraccolo · 2022 · British Journal of Cancer
2. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis
   Hao‐Xiang Wu, Yi‐Qian Pan, Ye He, Zixian Wang, Wen‐Long Guan, Yan‐Xing Chen, Yichen Yao, Ning‐Yi Shao, Rui‐Hua Xu, Feng Wang · 2022 · Journal of Clinical Oncology
3. Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
   Jan Budczies, Anja Seidel, Petros Christopoulos, Volker Endris, Matthias Kloor, Balázs Győrffy, Barbara Seliger, Peter Schirmacher, Albrecht Stenzinger, Carsten Denkert · 2018 · OncoImmunology
4. Evolving trends in lung cancer
   Ramakant Deshpand, Manish Chandra, Amit Rauthan · 2022 · Indian Journal of Cancer
5. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
   Tony S.K. Mok, G. Lopes, Byoung Chul Cho, Dariusz Mirosław Kowalski, Kazuo Kasahara, Yi-Long Lung Cancer Wu, Gilberto de Castro, H.Z. Turna, Răzvan Cristescu, Deepti Aurora-Garg et al. · 2023 · Annals of Oncology
6. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
   Katsutoshi Sekine, Shintaro Kanda, Yasushi Goto, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Noriko Motoi, Yuichiro Ohe · 2018 · Lung Cancer
7. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
   Zhangfeng Huang, Wenhao Su, Tong Lu, Yuanyong Wang, Yanting Dong, Yi Qin, Dahai Liu, Lili Sun, Wenjie Jiao · 2020 · Frontiers in Pharmacology
8. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer
   Joanna Jagieła, Piotr Bartnicki, Jacek Rysz · 2021 · International Journal of Molecular Sciences
9. Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
   Nathan Singh, Junwei Shi, Carl H. June, Marco Ruella · 2017 · Current Hematologic Malignancy Reports
10. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment
    Elie Rassy, Angela Botticella, Joseph Gergi Kattan, Cecile Le Pechoux, Benjamin Besse, Lizza E.L. Hendriks · 2018 · Cancer Treatment Reviews
11. Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
    Yanis Boumber · 2018 · Journal of Thoracic Disease
12. JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer
    Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya et al. · 2022 · Cancer
13. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
    Alexander Liede, Rohini K. Hernandez, Sally W. Wade, Ronghai Bo, Nathan Coleman Nussbaum, Elizabeth Stephanie Ahern, William C. Dougall, Mark John Smyth · 2018 · OncoImmunology
14. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Jingjing Qu, Quanhui Mei, Li Liu, Tianli Cheng, Peng Wang, Lijun Chen, Jianying Zhou · 2021 · Therapeutic Advances in Medical Oncology
15. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
    Heinz‐Josef Lenz, Aparna R. Parikh, David Robert Spigel, Allen Lee Cohn, Takayuki Yoshino, Mark D. Kochenderfer, Elena Élez, Spencer H. Shao, Dustin A. Deming, Regan C. Holdridge et al. · 2024 · Journal for ImmunoTherapy of Cancer
16. “How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
    Thomas William LeBlanc, Jennifer S. Temel, Paul R. Helft · 2018 · American Society of Clinical Oncology Educational Book
17. PD-1/PD-L1 Axis in Lung Cancer
    Fernando Costa Santini, Matthew David Hellmann · 2018 · The Cancer Journal
18. Predictors for Clinical Benefit of Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
    Hazem Edmond El-Osta, Syed Hasan Raza Jafri · 2019 · Immunotherapy
19. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer
    Jon Zugazagoitia, Yuting Liu, Maria I Toki, John McGuire, Fahad Shabbir Ahmed, Brian S. Henick, Richa Gupta, Scott N. Gettinger, Roy S. Herbst, Kurt Alex Schalper et al. · 2019 · Journal of Thoracic Oncology
20. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma
    Chenghan Luo, Mengyuan Lei, Yixia Zhang, Qian Zhang, Lifeng Li, Jingyao Lian, Shasha Liu, Liping Wang, Guofu Pi, Yi Zhang · 2019 · Journal of Cellular and Molecular Medicine
21. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients
    Qiao Yang, Mingjing Chen, Jiaoyang Gu, Kai Niu, Xianlan Zhao, Linpeng Zheng, Zihan Xu, Yongxin Yu, Feng Li, Lingxin Meng et al. · 2021 · Frontiers in Immunology
22. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
    Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, Carolyn Jean Presley, Cary Philip Gross · 2023 · JAMA Oncology
23. The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
    Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara · 2017 · Clinical Lung Cancer
24. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
    Derosa, Lisa, Routy, Bertrand, Kroemer, Guido, Zitvogel, Laurence · 2018 · OncoImmunology
25. Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
    Daniel E. Meyers, Paul Bryan, Shantanu Otto Banerji, Don G. Morris · 2018 · Current Oncology
26. Liquid biopsy tracking of lung tumor evolutions over time
    Alessandro Russo, Diego de Miguel‐Pérez, Muthukumar Gunasekaran, Katherine Ann Scilla, Rena S. Lapidus, Brandon Cooper, Ranee Mehra, Vincenzo Adamo, Umberto Malapelle, Christian Diego Rolfo · 2019 · Expert Review of Molecular Diagnostics
27. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
    Grzegorz Sławiński, Anna Wrona, Alicja Dąbrowska-Kugacka, Grzegorz Raczak, Ewa Lewicka · 2020 · International Journal of Molecular Sciences
28. Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
    Diego Hernán Enrico, Angélo Paci, Nathalie Chaput, Eleni Karamouza, Benjamin Besse · 2019 · Clinical Cancer Research
29. Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
    William Bennion McKean, Justin C. Moser, David L. Rimm, Siwen Hu‐Lieskovan · 2020 · American Society of Clinical Oncology Educational Book
30. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
31. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
    Gao, Ge, Liao, Weiting, Ma, Qizhi, Zhang, Benxia, Chen, Yue, Wang, Yongsheng · 2020 · Lung Cancer
32. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
    Siwen Hu‐Lieskovan, Aaron Elliott Lisberg, Jesse Meir Zaretsky, Tristan Grogan, Hira A. Rizvi, Daniel K. Wells, James Carroll, Amy Lauren Cummings, John Madrigal, Benjamin Jones et al. · 2019 · Clinical Cancer Research
33. Molecular Pathology of Lung Cancer
    James Joseph Saller, Theresa A. Boyle · 2021 · Cold Spring Harbor Perspectives in Medicine
34. Combining immunotherapy and radiotherapy in lung cancer
    Neeraj Bhalla, Rachel C. Brooker, Michael Brada · 2018 · Journal of Thoracic Disease
35. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors
    Bishal Gyawali, Spencer Phillips Hey, Aaron Seth Kesselheim · 2018 · JAMA Network Open
36. Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review
    Gaia Ninatti, Margarita Kirienko, Emanuele Neri, Martina Sollini, Arturo Chiti · 2020 · Diagnostics
37. Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
    Giulia Longhi, Douwe van Sinderen, Marco Ventura, Francesca Turroni · 2020 · Frontiers in Microbiology
38. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
    C.M. Kim, Jii Bum Lee, Sang Joon Shin, Joong Bae Ahn, Min‐Ji Lee, Han Sang Kim · 2022 · ESMO Open
39. Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
    Chaoyuan Liu, Wei Zhao, Junpeng Xie, Huashan Lin, Xingsheng Hu, Chang Li, Youlan Shang, Yapeng Wang, Yingjia Jiang, Meng-Ge Ding et al. · 2023 · Frontiers in Immunology
40. Computational immunogenomic approaches to predict response to cancer immunotherapies
    Venkateswar Addala, Felicity Newell, John V. Pearson, ALEC JAMES REDWOOD, Bruce W.S. Robinson, Jenette Creaney, Nicola Waddell · 2023 · Nature Reviews Clinical Oncology
41. Immune checkpoint inhibitors: new strategies to checkmate cancer
    Ruairí Wilson, Thomas R. Jeffry Evans, Alasdair R. Fraser, Robert J. B. Nibbs · 2017 · Clinical & Experimental Immunology
42. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
    Elizabeth Dudnik, Elias Bshara, Ahuva Grubstein, Ludmila Fridel, Tzippy Shochat, Laila C. Roisman, Maya Ilouze, Anna Belilovski Rozenblum, Smadar Geva, Alona Zer et al. · 2018 · Lung Cancer
43. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
    Claire Perrinjaquet, Nicolas Desbaillets, Andreas Felix Hottinger · 2019 · Current Opinion in Neurology
44. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
    Virginie Lemiale, Anne‐Pascale Meert, François Vincent, Michaël Darmon, Philippe R. Bauer, Andry Van de Louw, Élie Azoulay · 2019 · Annals of Intensive Care
45. Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
    Zimu Gong, Yinghong Wang · 2020 · JCO Oncology Practice
46. Identification of a Novel Tumor Microenvironment–Associated Eight-Gene Signature for Prognosis Prediction in Lung Adenocarcinoma
    Chao Ma, Huan Luo, Jing Cao, Xiangyu Zheng, Jinjun Zhang, Yanmin Zhang, Zongqiang Fu · 2020 · Frontiers in Molecular Biosciences
47. Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer
    Xinan Wang, Biagio Ricciuti, Joao V. Alessi, Tom T. Nguyen, Mark Magdi Awad, Xihong Lin, Bruce Evan Johnson, David C. Christiani · 2021 · JNCI Journal of the National Cancer Institute
48. Pembrolizumab for Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
    Smita Suhas Joshi, Steven Brad Maron, Daniel V.T. Catenacci · 2017 · Future Oncology
49. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis
    Sibo Tian, Jeffrey M. Switchenko, Zachary S. Buchwald, Pretesh R Patel, Joseph W. Shelton, Shannon Kahn, Rathi Narayana Pillai, Conor Ernst Steuer, Taofeek Kunle Owonikoko, Madhusmita Behera et al. · 2020 · International Journal of Radiation Oncology*Biology*Physics
50. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
    Matthew W. Rosenbaum, Benjamin J. Gigliotti, Sara Isabel Pai, Sareh Parangi, Heather Wachtel, Mari A. Mino-Kenudson, Viswanath Gunda, William C. Faquin · 2018 · Endocrine Pathology
51. Liquid Biopsy to Identify Actionable Genomic Alterations
    Sai‐Hong Ignatius Ou, Misako Nagasaka, Viola Weijia Zhu · 2018 · American Society of Clinical Oncology Educational Book
52. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
    Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen et al. · 2019 · Journal for ImmunoTherapy of Cancer
53. Role of DNA repair defects in predicting immunotherapy response
    Jing Zhang, David J. H. Shih, Shiaw‐Yih Lin · 2020 · Biomarker Research
54. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC
    Masayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda, Daisuke Takayanagi, Kouya Shiraishi, Takashi Kubo, Sachiyo Mitani, Yuji Matsumoto, Ken Masuda, Yuki Shinno et al. · 2021 · Journal of Thoracic Oncology
55. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
    Ying Yang, Hongyang Liu, Youming Chen, Nan Xiao, Zhaoyang Zheng, Hongchun Liu, Junhu Wan · 2023 · Cell Death and Disease
56. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
    Michael Frumovitz, Shannon Neville Westin, Gloria Salvo, Abdulrazzak Zarifa, Mingxuan Xu, Timothy Anthony Yap, Jordi Ahnert Rodon, Daniel D. Karp, Abdulrahman Abonofal, Amir Anthony Jazaeri et al. · 2020 · Gynecologic Oncology
57. Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
    Fenizia, Francesca, Pasquale, Raffaella, Roma, Cristin, Bergantino, Francesca, Iannaccone, Alessia, Normanno, Nicola · 2018 · Translational Lung Cancer Research
58. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
    Hélène Blons, Simon Garinet, Pierre Laurent‐Puig, Jean‐Baptiste Oudart · 2019 · Journal of Thoracic Disease
59. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
    Sylvie Lantuéjoul, Diane Damotte, Véronique Hofman, Julien Adam · 2019 · Journal of Thoracic Disease
60. Beyond PD-L1 Markers for Lung Cancer Immunotherapy
    Kamila Wojas‐Krawczyk, Ewa Kalinka‐Warzocha, Anna Grenda, Paweł Adam Krawczyk, Janusz Milanowski · 2019 · International Journal of Molecular Sciences
61. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor–Related Thyroid Disorders
    Chanjuan Ma, Frank Stephen Hodi, Anita Giobbie‐Hurder, Xiaochen Wang, Jing Zhou, Amy Zhang, Ying Zhou, Fei Mao, Trevor E. Angell, Chelsea Andrews et al. · 2019 · Cancer Immunology Research
62. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
    Elena Shklovskaya, Helen Rizos · 2021 · International Journal of Molecular Sciences
63. Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Wenhua Zhao, Wei Jiang, Huilin Wang, Jianbo He, Cuiyun Su, Qitao Yu · 2021 · Frontiers in Oncology
64. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
    Pinhao Fang, Jianfeng Zhou, Zhiwen Liang, Yu‐Shang Yang, Siyuan Luan, Xin Xiao, Xiaokun Li, Hanlu Zhang, Qixin Shang, Xiaoxi Zeng et al. · 2022 · Frontiers in Immunology
65. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
    Stephen L. Wang, Timothy An-thy Chan · 2025 · Cancer Cell
66. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer
    Fei Liang, Shaotian Zhang, Q. Wang, Wenyuan Li · 2018 · Annals of Oncology
67. Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic non-small cell lung cancer
    Mehmet Salih İyikesici · 2019 · International Journal of Hyperthermia
68. Liquid biopsy in tumors: opportunities and challenges
    Yi Bai, Haitao Zhao · 2018 · Annals of Translational Medicine
69. NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
    Matthew A. Gubens, Marianne J Davies · 2019 · PubMed
70. Do immune checkpoint inhibitors need new studies methodology?
    Roberto Ferrara, Sara Pilotto, Mario Caccese, Giulia Grizzi, Isabella Sperduti, Diana Giannarelli, Michèle Milella, Benjamin Besse, Giampaolo Tortora, Emilio Bria · 2018 · Journal of Thoracic Disease
71. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Liam M. Masterson, James E.F. Howard, Jazmina L. Gonzalez Cruz, Christopher C. Jackson, Catherine M. E. Barnett, Lewis Overton, Howard Yu-hao Liu, Rahul Ladwa, Fiona Simpson, Margie McGrath et al. · 2020 · International Journal of Cancer
72. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data
    Antonio Passaro, Ilaria Attili, Stefania Morganti, Ester Del Signore, Letizia Gianoncelli, Gianluca Spitaleri, Valeria Stati, Chiara Catania, Giuseppe Curigliano, Filippo de Marinis · 2020 · Cancer Treatment Reviews
73. Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy
    Xintong Li, Zhe Li, Hanyang Yu · 2020 · Chemical Communications
74. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Keiichiro Mori, Mohammad M. Abufaraj, Hadi Mostafaei, Fahad Quhal, Harun Fajković, Mesut Remzi A, Pierre I. Karakiewicz, Shin Egawa, Manuela Schmidinger, Shahrokh François Shariat et al. · 2020 · European Urology
75. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
    Hironori Uruga, Mari A. Mino-Kenudson · 2021 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
76. Immunotherapy in non-small cell lung cancer: update and new insights
    Xabier Mielgo-Rubio, Eider Azkona Uribelarrea, Laura Quintanta Cortés, M. Sereno Moyano · 2021 · Journal of Clinical and Translational Research
77. ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer
    Guangsheng Zhu, Ruifeng Shi, Li Y, Zihe Zhang, Songlin Xu, Chen Chen, Peijun Cao, Hongbing Zhang, Minghui Liu, Zhenhua Pan et al. · 2021 · Frontiers in Immunology
78. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
    Vito Amoroso, F. Gallo, Andrea Alberti, D. Paloschi, W. Ferrari Bravo, Assunta Esposito, Deborah Cosentini, Salvatore Grisanti, Rebecca Pedersini, Fausto Petrelli et al. · 2023 · ESMO Open
79. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
    Jordi Remón, Laura Mezquita, Jesus Corral, Noelia Vilariño, Noemı́ Reguart · 2018 · Journal of Thoracic Disease
80. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
    Arsen Osipov, Adrian Gerard Murphy, Lei Zheng · 2019 · Advances in cancer research
81. Feasibility Study of Nivolumab as Neoadjuvant Chemotherapy for Locally Esophageal Carcinoma: FRONTiER (JCOG1804E)
    Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Takashi Kojima, Hiroki Hara, Tetsuya Abe, Yasuhiro Tsubosa, Kengo Nagashima, Kazunori Aoki, Yukihiro Mizoguchi et al. · 2020 · Future Oncology
82. Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
    Alessandra Cesano, Sarah E. Warren · 2018 · Biomedicines
83. New Treatment Options in Advanced Squamous Cell Lung Cancer
    Paul K. Paik, Rathi Narayana Pillai, Christopher S. Lathan, Sylvia V. Alarcon, Vassiliki A. Papadimitrakopoulou · 2019 · American Society of Clinical Oncology Educational Book
84. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
    Zhihao Lü, Huan Chen, Shuang Li, Jifang Gong, Jian Li, Jianling Zou, Lihong Wu, Jianing Yu, Wenbo Han, Huaibo Sun et al. · 2020 · Journal for ImmunoTherapy of Cancer
85. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
    Wang, Manni, Liu, Yu, Cheng, Yuan, Wei, Yuquan, Wei, Xiawei · 2019 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
86. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
    Baxi, Vipul, Lee, George, Duan, Chunzhe, Pandya, Dimple, Cohen, Daniel N., Edwards, Robin, Chang, Han, Li, Jun, Elliott, Hunter, Pokkalla, Harsha et al. · 2022 · Modern Pathology
87. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
    Haibo Mou, Lanfang Yu, Qin Liao, Xuehua Hou, Yinfang Wu, Qiang Cui, Na Yan, Ruobing Ma, Lingjian Wang, Ming Yao et al. · 2018 · BMC Cancer
88. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
    Jia-xin Zhu, Tiantian Zhang, Jiahao Li, Junming Lin, Wenhua Liang, Wenjie Huang, Ning Wan, Jie Jiang · 2019 · Frontiers in Pharmacology
89. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma
    Qian Xing, Zhongwei Zhang, Qionghua Lin, Lihua Shen, Pengmei Wang, Shan Zhang, Ming Fan, Biao Zhu · 2020 · Annals of Translational Medicine
90. Therapeutic potential of interleukin‑15 in cancer (Review)
    Gheorghița Isvoranu, Mihaela Surcel, Adriana Narcisa Munteanu, Ovidiu Gabriel Bratu, Florentina Ioniţă Radu, Monica Teodora Neagu, Marioara Chiritoiu‐Butnaru · 2021 · Experimental and Therapeutic Medicine
91. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
    Francesco Passiglia, Antonio Galvano, Marta Castiglia, Lorena Incorvaia, Valentina Calò, Angela Listì, Salvatore Mazzarisi, Alessandro Perez, Giuseppe Gallina, Sérgio Rizzo et al. · 2019 · Therapeutic Advances in Medical Oncology
92. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view
    Humera Memon, Bhoomika M. Patel · 2019 · Life Sciences
93. Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis
    Jiabu Ye, Xiang Ji, Phillip A. Dennis, Hesham A. Abdullah, Pralay Mukhopadhyay · 2020 · Clinical Pharmacology & Therapeutics
94. Biomarkers for Early Detection, Prognosis, and Therapeutics of Esophageal Cancers
    Vikrant Rai, Joe Abdo, Devendra K. Agrawal · 2023 · International Journal of Molecular Sciences
95. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
    Vanda F. Torous, Deepa Rangachari, Benjamin P. Gallant, Meghan Shea, Daniel Botelho Costa, Paul A. VanderLaan · 2018 · Journal of the American Society of Cytopathology
96. Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants
    Valerie Pestinger, Matthew Ryan Smith, Toju Sillo, John M. Findlay, Jean‐François Laes, Gerald Martin, Gary Middleton, Phillipe Taniere, Andrew David Beggs · 2020 · Molecular Diagnosis & Therapy
97. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
    Yibei Wang, Mohammed Safi, Fred R. Hirsch, Shun Lu, Solange Peters, Ramaswamy Govindan, Rafael Rosell, Keunchil Park, Jianjun J. Zhang · 2025 · Nature Reviews Clinical Oncology
98. The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
    Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli · 2019 · Cancers
99. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
    Alejandro Ruíz-Patiño, Oscar G. Arrieta, Andrés Felipe Cardona, Claudio Marcelo Martin, Luis Estuardo Raez, Zyanya Lucía Zatarain-Barrón, Feliciano Barrón, Luisa Ricaurte, María A. Bravo-Garzón, Luis A. Mas et al. · 2019 · Thoracic Cancer
100. Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
     Jiaxin Li, Jumin Huang, Zebo Jiang, Runze Li, Ao Sun, Elaine Lai‐Han Leung, Peiyu Yan · 2019 · Integrative Cancer Therapies